DNA-vaccine platform development against H1N1 subtype of swine influenza a viruses

Viral Immunology

Volumn 25, Issue 4, 2012, Pages 297-305

  Wei, Huiling ^a   Lenz, Stephen D ^a   Thompson, David H ^b   Pogranichniy, Roman M ^a  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; EPITOPE; GAMMA INTERFERON; INFLUENZA VACCINE; PLASMID DNA; PROTEIN VP22; RECOMBINANT PROTEIN;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOMEGALOVIRUS; DNA VECTOR; DRUG SYNTHESIS; GENE EXPRESSION; GENE SEQUENCE; GENETIC TRANSFECTION; HERPES SIMPLEX VIRUS 1; HUMORAL IMMUNITY; INFLUENZA VIRUS A H1N1; INTRON; MOUSE; NONHUMAN; NORTH AMERICA; PROMOTER REGION; SWINE INFLUENZA VIRUS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; CATTLE; CELL LINE; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; ORTHOMYXOVIRIDAE INFECTIONS; RECOMBINANT FUSION PROTEINS; SWINE; SWINE DISEASES; VACCINES, DNA; VIRAL STRUCTURAL PROTEINS;

EID: 84864973149     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2011.0093     Document Type: Article

References (44)

1. Olsen CW, Brown JH, Easterday BC, and Van Reeth K: Swine Influenza. In: Diseases of Swine, 9th ed. (Straw BE, Zimmerman JJ, D'Allaire S, and Taylor DJ, eds.). Wiley-Blackwell, Ames, IA, 2006.
2. Shope RE: The etiology of swine influenza. Science 1931;73: 214-215.
3. Vincent AL, Ma W, Lager KM, Janke BH, and Richt JA: Swine influenza viruses a North American perspective. Adv Virus Res 2008;72:127-154.
4. Myers KP, Olsen CW, and Gray GC: Cases of swine influenza in humans: A review of the literature. Clin Infect Dis 2007;44:1084-1088.
5. Cox RJ, Brokstad KA, and Ogra P: Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 2004;59:1-15.
6. Tamura S, Tanimoto T, and Kurata T: Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis 2005;58:195-207.
7. Olsen CW: DNA vaccination against influenza viruses: A review with emphasis on equine and swine influenza. Vet Microbiol 2000;74:149-164.
8. Bui HH, Peters B, Assarsson E, Mbawuike I, and Sette A: Ab and T cell epitopes of influenza A virus, knowledge and opportunities. Proc Natl Acad Sci USA 2007;104:246-251.
9. Laddy DJ, Yan J, Corbitt N, Kobasa D, Kobinger GP, and Weiner DB: Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine 2007;25:2984-2989.
10. Matrosovich M, Klenk HD, and Kawaoka Y: Receptor specificity, host-range, and pathogenicity of influenza viruses. In: Influenza Virology: Current Topics. Kawaoka Y, (ed.). Caister Academic Press, Wymondham, 2006, pp. 95-137.
11. Wang S, Taaffe J, Parker C, et al.: Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codonoptimized HA DNA vaccines. J Virol 2006;80:11628-11637.
12. Kozak M: At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J Mol Biol 1987;196:947-950.
13. Olafsdottir G, Svansson V, Ingvarsson S, Marti E, and Torsteinsdottir S: In vitro analysis of expression vectors for DNA vaccination of horses: The effect of a Kozak sequence. Acta Vet Scand 2008;50:44.
14. Choi T, Huang M, Gorman C, and Jaenisch R: A generic intron increases gene expression in transgenic mice. Mol Cell Biol 1991;11:3070-3074.
15. Palmiter RD, Sandgren EP, Avarbock MR, Allen DD, and Brinster RL: Heterologous introns can enhance expression of transgenes in mice. Proc Natl Acad Sci USA 1991;88:478-482.
16. Zheng CF, Brownlie R, Huang DY, Babiuk LA, and van Drunen Littel-Yan Den Hurk S: Intercellular trafficking of the major tegument protein VP22 of bovine herpesvirus-1 and its application to improve a DNA vaccine. Arch Virol 2006; 151:985-993.
17. Liu W, and Chen YH: High epitope density in a single protein molecule significantly enhances antigenicity as well as immunogenicity: A novel strategy for modern vaccine development and a preliminary investigation about B cell discrimination of monomeric proteins. Eur J Immunol 2005; 35:505-514.
18. Zhao G, Lin Y, Du L, et al.: An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol J 2010;7:9.
19. Zhao G, Du L, Xiao W, et al.: Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant. Vaccine 2010;28:7233-7240.
20. Nakayama K: Furin: A mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. Biochem J 1997;327:625-635.
21. Lu J, Wettstein PJ, Higashimoto Y, Appella E, and Celis E: TAP-independent presentation of CTL epitopes by Trojan antigens. J Immunol 2001;166:7063-7071.
22. Lu J, Higashimoto Y, Appella E, and Celis E: Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J Immunol 2004;172: 4575-4582.
23. Oishi Y, Onozuka A, Kato H, Shimura N, Imai S, and Nisizawa T: The effect of amino acid spacers on the antigenicity of dimeric peptide-inducing cross-reacting antibodies to a cell surface protein antigen of Streptococcus mutans. Oral Microbiol Immunol 2001;16:40-44.
24. Lennon-Dumenil AM, Bakker AH, Wolf-Bryant P, Ploegh HL, and Lagaudriere-Gesbert C: A closer look at proteolysis and MHC-class-II-restricted antigen presentation. Curr Opin Immunol 2002;14:15-21.
25. Yano A, Onozuka A, Asahi-Ozaki Y, et al.: An ingenious design for peptide vaccines. Vaccine 2005;23:2322-2326.
26. Liang R, van Den Hurk JV, Babiuk LA, and van Drunen Littel-Yan Den Hurk S: Priming with DNA encoding E2 and boosting with E2 protein formulated with CpG oligodeoxynucleotides induces strong immune responses and protection from bovine viral diarrhea virus in cattle. J Gen Virol 2006;87:2971-2982.
27. Ben-Yedidia T, Marcus H, Reisner Y, and Arnon R: Intranasal administration of peptide vaccine protects human/ mouse radiation chimera from influenza infection. Int Immunol 1999;11:1043-1051.
28. Arnon R, Tarrab-Hazdai R, and Ben-Yedidia T: Peptidebased synthetic recombinant vaccines with anti-viral efficacy. Biologicals 2001;29:237-242.
29. Berkhoff EG, Geelhoed-Mieras MM, Fouchier RA, Osterhaus AD, and Rimmelzwaan GF: Assessment of the extent of variation in influenza A virus cytotoxic T-lymphocyte epitopes by using virus-specific CD8 + T-cell clones. J Gen Virol 2007;88:530-535.
30. Adar Y, Singer Y, Levi R, et al.: A universal epitope-based influenza vaccine and its efficacy against H5N1. Vaccine 2009;27:2099-2107.
31. Crowe SR, Miller SC, Shenyo RM, and Woodland DL: Vaccination with an acidic polymerase epitope of influenza virus elicits a potent antiviral T cell response but delayed clearance of an influenza virus challenge. J Immunol 2005; 174:696-701.
32. Crowe SR, Miller SC, and Woodland DL: Identification of protective and non-protective T cell epitopes in influenza. Vaccine 2006;24:452-456.
33. Kreijtz JH, Bodewes R, van Amerongen G, et al.: Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 2007;25:612-620.
34. Levi R, and Arnon R: Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection. Vaccine 1996;14:85-92.
35. Jeon SH, Ben-Yedidia T, and Arnon R: Intranasal immunization with synthetic recombinant vaccine containing multiple epitopes of influenza virus. Vaccine 2002;20:2772-2780.
36. Li H, Ding J, and Chen YH: Recombinant protein comprising multi-neutralizing epitopes induced high titer of antibodies against influenza A virus. Immunobiology 2003;207:305-313.
37. Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, and Cox NJ: Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 1995;13:1399-1402.
38. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, and Fiers W: A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999;5: 1157-1163.
39. Jegerlehner A, Schmitz N, Storni T, and Bachmann MF: Influenza A vaccine based on the extracellular domain of M2: Weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004;172:5598-5605.
40. De Filette M, Min Jou W, Birkett A, et al.: Universal influenza A vaccine: optimization of M2-based constructs. Virology 2005;337:149-161.
41. De Filette M, Ramne A, Birkett A, et al.: The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 2006;24:544-551.
42. Ernst WA, Kim HJ, Tumpey TM, et al.: Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 2006;24:5158-5168.
43. Zhang GG, Li DX, Zhang HH, Zeng YM, and Chen L: Enhancement of mucosal immune response against the M2eHBc + antigen in mice with the fusion expression products of LTB and M2eHBc + through mucosal immunization route. Vet Res Commun 2009;33:735-747.
44. Levi R, Aboud-Pirak E, Leclerc C, Lowell GH, and Arnon R: Intranasal immunization of mice against influenza with synthetic peptides anchored to proteosomes. Vaccine 1995;3: 1353-1359.